Lilly gains extension on Cymbalta exclusivity

July 6 (Reuters) - Eli Lilly & Co said on Friday that it gained six more months of U.S. exclusivity on its Cymbalta anti-depressant for conducting pediatric studies, extending Lilly's hold on the…
Read the full story: Reuters: Healthcare